

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231

On July 1, 2002

By Victoria A. MacMillan
Victoria A. MacMillan

COPY

Attorney Docket No. 0212us310

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Anders Hjelholt Pedersen, *et al.*

Application No.: 09/782,587

Filed: February 12, 2001

For: Factor VII or VIIa-like Molecules.

Examiner: Unassigned

Art Unit: 1774

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR § 1.97 and § 1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-SB/08 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Application No. 09/782,587

Page 2

COPY

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to a first Office action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above noted Deposit Account.

Respectfully submitted,



Joanne R. Petithory
Reg. No. 42,995

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560

(Modified) PTO/SB08A (11/96)
Approved for use through 10/31/99. OMB 0551-0002

Substitute for form 1449A-B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/782,587
	Filing Date	February 12, 2001
	First Named Inventor	Anders Hjelholt Pedersen, et al.
	Group Art Unit	1744
	Examiner Name	Unassigned
	Attorney Docket Number	0212us310

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Documents		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T
	1	CHEUNG, WING-FAI et al., "Localization Of An E0pitope Of A Calcium-Dependent Monoclonal Antibody To The N-Terminal Region Of The GLA Domain Of Human Factor VII", <i>Thrombosis Research</i> , (1995), 79(2): 199-206			
	2	DICKINSON, CRAIG D. et al., "Influence of Cofactor Binding and Active Site Occupancy on the Conformation of the Macromolecular Substrate Exosite Of Factor VIIa", <i>J. Mol. Bio.</i> (1998) 277:959-971			
	3	JIN, JIANPING et al., "Four Loops of the Catalytic Domain of Factor VIIa Mediate the Effect of the First EGF-like Domain Substitution on Factor VIIa Catalytic Activity", <i>J. Mol. Bio.</i> (2001) 307:1503-1517			
	4	NEUENSCHWANDER, PIERRE F. et al., "Alteration of the Substrate and Inhibitor Specificities of Blood Coagulation Factor VIIa: Importance of Amino Acid Residue K192", <i>Biochemistry</i> , (1995) 34:8701-8707			
Examiner Signature		Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.